Skip to main contentAll experts

MsJulie Berthy

AST SCTST

MD-PEDIATRICS

Orcid identifier0000-0002-1058-3639 (opens in a new tab)⁠
  • AST SCTST
    MD-PEDIATRICS

GRANTS

  • GRANT
    Registry Study to Observe Long-Term Safety of Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy, Protocol # DMD-001
    Catalyst Pharmaceuticals24 Jul 2025 - 23 Jul 2030
    Active
  • GRANT
    Research ECHO
    University of Florida20 Feb 2024 - 19 Feb 2029
    Active
  • GRANT
    A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy
    Edgewise Therapeutics14 Dec 2023 - 13 Dec 2028
    Active
  • GRANT
    A 2-Part, Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics and Biomarkers in Children with Duchenne Muscular Dystrophy, which includes a Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Part A Followed by Part B, an Open-Label Extension
    Edgewise Therapeutics9 May 2023 - 8 May 2028
    Active
  • GRANT
    A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)
    Biohaven Pharmaceuticals4 Oct 2022 - 2 Oct 2027
    Active
  • GRANT
    LifeGlider - mobility device solution to falls and loss of ambulation
    UF Medical Guild22 Sep 2022 - 31 May 2025
    Expired
  • GRANT
    Task Order #8: Documentation and Development in support of Clinical Programs in Friedreich’s Ataxia
    *aavantibio25 Jan 2021 - 31 Dec 2022
    Expired